🇺🇸 FDA
Patent

US 9169249

Protein kinase C inhibitors and uses thereof

granted A61KA61K31/506A61P

Quick answer

US patent 9169249 (Protein kinase C inhibitors and uses thereof) held by Rigel Pharmaceuticals, Inc. expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/506, A61P, A61P27/02, A61P29/00